Milner Consortium reaches 10

Milner Consortium reaches 10

We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the past month. Now with ten pharma partners and three academic partners, this has become one of the largest cross-sector...
Start Codon closes new £15 million venture fund

Start Codon closes new £15 million venture fund

Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups,...
OncoInnovation: TGIO 2020 Challenge winner

OncoInnovation: TGIO 2020 Challenge winner

Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early Detection and OncoInnovation  – together with the University Enterprise Zone. The OncoInnovation programme is delivered in the...
Kostas Tzelepis awarded John Goldman Fellowship

Kostas Tzelepis awarded John Goldman Fellowship

We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a relevant...
Start Codon closes new £15 million venture fund

Start Codon announces first cohort of companies

Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were enrolled in the programme this February and will debut at the Milner Symposium event this Friday June 26th and ONHelix...
Eisai join Milner Therapeutics Consortium

Eisai join Milner Therapeutics Consortium

We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai’s corporate mission is defined...

MILNER THERAPEUTICS SYMPOSIUM

X